(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

First approval in the US for AstraZeneca (AZN) and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy ...

The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for adults with unresectable or ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

Patients with HR-positive metastatic breast cancer can expect to undergo biomarker testing both at diagnosis and again if the disease progresses. Patients with hormone receptor (HR)-positive ...

“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...

Survival results for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy Trial previously met the dual primary ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which ...